BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780)
South Korea
· Delayed Price · Currency is KRW 4,340.00
-50.00 (-1.14%)
Apr 1, 2025, 3:30 PM KST
BCWORLD PHARM. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Operating Revenue | 74,814 | 75,111 | 72,703 | 62,079 | 57,030 | Upgrade
|
| Other Revenue | -0 | - | -0 | - | -0 | Upgrade
|
| Revenue | 74,814 | 75,111 | 72,703 | 62,079 | 57,030 | Upgrade
|
| Revenue Growth (YoY) | -0.40% | 3.31% | 17.11% | 8.85% | 10.74% | Upgrade
|
| Cost of Revenue | 46,803 | 43,234 | 45,497 | 42,149 | 36,679 | Upgrade
|
| Gross Profit | 28,012 | 31,876 | 27,206 | 19,931 | 20,351 | Upgrade
|
| Selling, General & Admin | 15,945 | 16,127 | 21,261 | 11,662 | 10,850 | Upgrade
|
| Research & Development | 7,779 | 6,141 | 770.66 | 9,298 | 10,951 | Upgrade
|
| Other Operating Expenses | 302.2 | 132.24 | 58.84 | 200.34 | 219.58 | Upgrade
|
| Operating Expenses | 26,512 | 25,511 | 25,344 | 21,464 | 22,448 | Upgrade
|
| Operating Income | 1,500 | 6,365 | 1,862 | -1,534 | -2,096 | Upgrade
|
| Interest Expense | -4,760 | -5,234 | -3,792 | -2,169 | -2,418 | Upgrade
|
| Interest & Investment Income | 207.91 | 187.98 | 129.42 | 180.31 | 221.69 | Upgrade
|
| Currency Exchange Gain (Loss) | 54.35 | 110.63 | 376.05 | 317.28 | -367.75 | Upgrade
|
| Other Non Operating Income (Expenses) | 240.24 | -285.96 | 501.3 | 498.41 | 1,634 | Upgrade
|
| EBT Excluding Unusual Items | -2,758 | 1,144 | -923.13 | -2,707 | -3,026 | Upgrade
|
| Gain (Loss) on Sale of Investments | -28.94 | 13.42 | -535.17 | -229.14 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 20.77 | 48.91 | -0.32 | -0 | 198.74 | Upgrade
|
| Asset Writedown | - | - | -64.29 | - | -2.36 | Upgrade
|
| Pretax Income | -2,766 | 1,206 | -1,523 | -2,936 | -2,830 | Upgrade
|
| Income Tax Expense | 550.12 | -1,686 | -1,583 | 42.06 | -635.66 | Upgrade
|
| Earnings From Continuing Operations | -3,316 | 2,892 | 59.78 | -2,978 | -2,194 | Upgrade
|
| Minority Interest in Earnings | -1,116 | -258.52 | 221.52 | 1,135 | 614.15 | Upgrade
|
| Net Income | -4,433 | 2,634 | 281.3 | -1,843 | -1,580 | Upgrade
|
| Net Income to Common | -4,433 | 2,634 | 281.3 | -1,843 | -1,580 | Upgrade
|
| Net Income Growth | - | 836.31% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Change (YoY) | - | -0.98% | -0.19% | 0.35% | -0.73% | Upgrade
|
| EPS (Basic) | -477.52 | 283.74 | 30.01 | -196.23 | -168.80 | Upgrade
|
| EPS (Diluted) | -477.52 | 283.74 | 30.01 | -196.23 | -168.80 | Upgrade
|
| EPS Growth | - | 845.59% | - | - | - | Upgrade
|
| Free Cash Flow | 1,644 | 8,361 | 666.21 | -18,064 | -13,288 | Upgrade
|
| Free Cash Flow Per Share | 177.15 | 900.71 | 71.07 | -1923.27 | -1419.62 | Upgrade
|
| Dividend Per Share | 90.909 | - | - | - | 90.909 | Upgrade
|
| Gross Margin | 37.44% | 42.44% | 37.42% | 32.10% | 35.69% | Upgrade
|
| Operating Margin | 2.00% | 8.47% | 2.56% | -2.47% | -3.68% | Upgrade
|
| Profit Margin | -5.92% | 3.51% | 0.39% | -2.97% | -2.77% | Upgrade
|
| Free Cash Flow Margin | 2.20% | 11.13% | 0.92% | -29.10% | -23.30% | Upgrade
|
| EBITDA | 9,194 | 13,835 | 9,070 | 3,641 | 2,473 | Upgrade
|
| EBITDA Margin | 12.29% | 18.42% | 12.48% | 5.86% | 4.34% | Upgrade
|
| D&A For EBITDA | 7,694 | 7,470 | 7,208 | 5,174 | 4,569 | Upgrade
|
| EBIT | 1,500 | 6,365 | 1,862 | -1,534 | -2,096 | Upgrade
|
| EBIT Margin | 2.00% | 8.47% | 2.56% | -2.47% | -3.68% | Upgrade
|
| Advertising Expenses | 922.8 | 1,274 | 1,505 | 1,085 | 728.19 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.